Details

Autor(en) / Beteiligte

• Garcia, Santiago
• Cubeddu, Robert J
• Hahn, Rebecca T
• Ternacle, Julien
• Kapadia, Samir R
• Kodali, Susheel K
• Thourani, Vinod H
• Jaber, Wael A
• Asher, Craig R
• Elmariah, Sammy
• Makkar, Raj
• Webb, John G
• Herrmann, Howard C
• Lu, Michael
• Devireddy, Chandan M
• Malaisrie, S Chris
• Smith, Craig R
• Mack, Michael J
• Sorajja, Paul
• Cavalcante, João L
• Goessl, Mario
• Shroff, Gautam R
• Leon, Martin B
• Pibarot, Philippe

Titel

5-Year Outcomes Comparing Surgical Versus Transcatheter Aortic Valve Replacement in Patients With Chronic Kidney Disease

Ist Teil von

• JACC. Cardiovascular interventions, 2021-09, Vol.14 (18), p.1995-2005

Ort / Verlag

United States

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of this study was to compare 5-year cardiovascular, renal, and bioprosthetic valve durability outcomes in patients with severe aortic stenosis (AS) and chronic kidney disease (CKD) undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Patients with severe AS and CKD undergoing TAVR or SAVR are a challenging, understudied clinical subset. Intermediate-risk patients with moderate to severe CKD (estimated glomerular filtration rate <60 mL/min/m ) from the PARTNER (Placement of Aortic Transcatheter Valve) 2A trial (patients randomly assigned to SAPIEN XT TAVR or SAVR) and SAPIEN 3 Intermediate Risk Registry were pooled. The composite primary outcome of death, stroke, rehospitalization, and new hemodialysis was evaluated using Cox regression analysis. Patients with and without perioperative acute kidney injury (AKI) were followed through 5 years. A core laboratory-adjudicated analysis of structural valve deterioration and bioprosthetic valve failure was also performed. The study population included 1,045 TAVR patients (512 SAPIEN XT, 533 SAPIEN 3) and 479 SAVR patients. At 5 years, SAVR was better than SAPIEN XT TAVR (52.8% vs 68.0%; P = 0.04) but similar to SAPIEN 3 TAVR (52.8% vs 58.7%; P = 0.89). Perioperative AKI was more common after SAVR than TAVR (26.3% vs 10.3%; P < 0.001) and was independently associated with long-term outcomes. Compared with SAVR, bioprosthetic valve failure and stage 2 or 3 structural valve deterioration were significantly greater for SAPIEN XT TAVR (P < 0.05) but not for SAPIEN 3 TAVR. In intermediate-risk patients with AS and CKD, SAPIEN 3 TAVR and SAVR were associated with a similar risk for the primary endpoint at 5 years. AKI was more common after SAVR than TAVR, and SAPIEN 3 valve durability was comparable with that of surgical bioprostheses.